Sugi Predict

Sugi Predict / Targets / EPOR

EPOR

Erythropoietin receptor · P19235 · EPOR on Sugi Atlas →

4,701 patent compounds predicted against EPOR, 1,591 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6808678 SCHEMBL6808678 0.69 10/20
SCHEMBL6890591 SCHEMBL6890591 0.52 10/20
SCHEMBL5498502 SCHEMBL5498502 0.59 9/20
SCHEMBL7447749 SCHEMBL7447749 0.50 9/20
SCHEMBL7447767 SCHEMBL7447767 0.50 9/20
SCHEMBL3899072 SCHEMBL3899072 0.68 8/20
SCHEMBL3903195 SCHEMBL3903195 0.68 8/20
SCHEMBL4327813 SCHEMBL4327813 0.55 8/20
SCHEMBL4327817 SCHEMBL4327817 0.55 8/20
SCHEMBL6809576 SCHEMBL6809576 0.55 8/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4279926) 0.54 8/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4279930) 0.54 8/20
SCHEMBL7111053 SCHEMBL7111053 0.48 8/20
SCHEMBL2438787 SCHEMBL2438787 0.58 7/20
SCHEMBL6831056 SCHEMBL6831056 0.56 7/20
SCHEMBL8942773 SCHEMBL8942773 0.52 7/20
SCHEMBL2437662 SCHEMBL2437662 0.51 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1134542) 0.43 7/20
Iodide Iodide (SCHEMBL1428394) 0.41 7/20
SCHEMBL3803671 SCHEMBL3803671 0.58 6/20

Clinical trials — most relevant to EPOR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparison Among Erythropoietin Stimulating Agents PHASE4COMPLETED
Ferric Citrate in ESRD Pilot Project PHASE4ACTIVE_NOT_RECRUITING
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II PHASE4UNKNOWN
Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Failure PHASE4UNKNOWN
Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation PHASE2/PHASE3COMPLETED
Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure PHASE3COMPLETED
Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure PHASE3COMPLETED
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions PHASE3ACTIVE_NOT_RECRUITING
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients PHASE3RECRUITING
A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia PHASE3COMPLETED
Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial) PHASE3RECRUITING
Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants PHASE3UNKNOWN
Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis PHASE3COMPLETED
A Randomized, Double-blinded, Active Controlled Crossover Clinical Trial to Investigate PK, PD and Safety of GBPD002 PHASE1/PHASE2COMPLETED
Topical Erythropoietin Hydrogel Formulation for Diabetic Foot Ulcers PHASE1/PHASE2COMPLETED
Erythropoietin Therapy for Subarachnoid Hemorrhage PHASE2COMPLETED
Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB PHASE2COMPLETED
Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain Injury PHASE2COMPLETED
Mild Encephalopathy in the Newborn Treated With Darbepoetin PHASE2COMPLETED
Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With Chronic Kidney Diseases Not on Dialysis PHASE2UNKNOWN
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms PHASE2ACTIVE_NOT_RECRUITING
Erythropoietin for Infants With Brain Injuries Due to Oxygen Deprivation at Birth PHASE1UNKNOWN
Erythropoietin in HIE Neonate EARLY_PHASE1NOT_YET_RECRUITING
The Role of Erythropoietin in Myelodysplastic Syndrome nanCOMPLETED
Studying Erythropoietin Receptor Presence and Function in Human Cancer Specimens nanUNKNOWN
Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery nanCOMPLETED
A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies nanWITHDRAWN
Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy nanWITHDRAWN
The Clinical Study for Evaluating The Safety And Efficacy Of Epodion® nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a EPOR binder may also engage these)

ProteinNameSimilarity
Q9MYZ9 — 1.000 Q9MYZ9 →
P14753 — 1.000 P14753 →
Q2KL21 — 1.000 Q2KL21 →
Q07303 — 1.000 Q07303 →
Q9HBE5 — 0.991 Q9HBE5 →
Q9JHX3 — 0.990 Q9JHX3 →
Q8IU57 — 0.990 Q8IU57 →
Q96F46 — 0.987 Q96F46 →
A0AAU7VAE8 — 0.987 A0AAU7VAE8 →
Q9HC73 — 0.987 Q9HC73 →
Q60837 — 0.986 Q60837 →
Q38J84 — 0.986 Q38J84 →
P26954 — 0.986 P26954 →
P32927 — 0.985 P32927 →
P14784 — 0.985 P14784 →
Q38J85 — 0.984 Q38J85 →
MPL Thrombopoietin receptor 0.984 landscape →
Q6UWB1 — 0.983 Q6UWB1 →
Q9UHF4 — 0.983 Q9UHF4 →
K7NAJ3 — 0.982 K7NAJ3 →
P16297 — 0.982 P16297 →
Q01114 — 0.982 Q01114 →
Q5RKR3 — 0.981 Q5RKR3 →
Q8R4S8 — 0.981 Q8R4S8 →
Q08351 — 0.981 Q08351 →
P22273 — 0.981 P22273 →
Q9ET35 — 0.981 Q9ET35 →
Q8N386 — 0.980 Q8N386 →
P26955 — 0.980 P26955 →
P26896 — 0.980 P26896 →